908 Devices (MASS) to Release Quarterly Earnings on Tuesday

908 Devices (NASDAQ:MASS - Get Free Report) will issue its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

908 Devices (NASDAQ:MASS - Get Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03. The business had revenue of $14.40 million for the quarter, compared to analyst estimates of $14.16 million. 908 Devices had a negative net margin of 72.47% and a negative return on equity of 21.09%. 908 Devices's revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.31) EPS. On average, analysts expect 908 Devices to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

908 Devices Stock Performance

908 Devices stock traded up $0.06 during midday trading on Wednesday, reaching $5.62. 159,155 shares of the stock were exchanged, compared to its average volume of 171,955. 908 Devices has a 52 week low of $4.85 and a 52 week high of $12.51. The firm has a market cap of $184.95 million, a PE ratio of -4.97 and a beta of 0.93. The company's fifty day moving average is $6.72 and its 200-day moving average is $7.08.

Insiders Place Their Bets

In other 908 Devices news, CEO Kevin J. Knopp sold 9,071 shares of the business's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total value of $63,497.00. Following the completion of the transaction, the chief executive officer now owns 411,981 shares of the company's stock, valued at approximately $2,883,867. The transaction was disclosed in a filing with the SEC, which is available through this link. In other 908 Devices news, CFO Joseph H. Iv Griffith sold 5,698 shares of the business's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total value of $39,886.00. Following the completion of the transaction, the chief financial officer now owns 89,711 shares of the company's stock, valued at approximately $627,977. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin J. Knopp sold 9,071 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total transaction of $63,497.00. Following the completion of the sale, the chief executive officer now directly owns 411,981 shares of the company's stock, valued at approximately $2,883,867. The disclosure for this sale can be found here. Insiders sold a total of 20,001 shares of company stock valued at $139,955 in the last quarter. Corporate insiders own 27.80% of the company's stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.